Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Imiquimod
Drug ID BADD_D01142
Description Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma.
Indications and Usage For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
Marketing Status approved; investigational
ATC Code D06BB10
DrugBank ID DB00724
KEGG ID D02500
MeSH ID D000077271
PubChem ID 57469
TTD Drug ID D06CTE
NDC Product Code 62350-0077; 68682-272; 72189-084; 0168-0432; 22365-121; 51672-4174; 99207-271; 66039-829; 71052-160; 64552-4008; 45802-368; 51552-1538; 62147-0087; 51672-4145; 63629-8818; 68462-536; 51927-0168; 72643-006; 0093-3133; 99207-260; 99207-270; 99207-276; 58175-0397; 62147-0072
UNII P1QW714R7M
Synonyms Imiquimod | 1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine | S 26308 | S-26308 | R 837 | R-837 | R837 | Zyclara | Aldara
Chemical Information
Molecular Formula C14H16N4
CAS Registry Number 99011-02-6
SMILES CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tinnitus04.04.01.002; 17.04.07.0040.002897%
Tooth disorder07.09.05.001---
Toothache07.09.06.001--
Toxic epidermal necrolysis10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.0080.000658%
Tremor17.01.06.002--
Trigeminal neuralgia17.04.08.0010.000439%-
Ulcer08.03.06.0010.001932%-
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urethral disorder20.07.01.002---
Urinary retention20.02.02.011--
Urinary tract disorder20.08.01.001---
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria10.01.06.001; 23.04.02.001--
Uterovaginal prolapse21.07.05.001---
Vaginal discharge21.08.02.0020.000439%
Vaginal infection11.01.10.002; 21.14.02.002--
Vertigo04.04.01.003; 17.02.12.0020.000439%
Viral infection11.05.04.001---
Vision blurred06.02.06.007; 17.17.01.0100.001624%
Visual impairment06.02.10.0130.001185%-
Vitiligo10.04.02.004; 23.05.02.0040.003117%-
Vomiting07.01.07.003--
Vulval disorder21.08.01.007---
Vulvitis11.01.10.007; 21.14.02.006--
White blood cell count13.01.06.027---
White blood cell count decreased13.01.06.012--
Application site vesicles08.02.01.009; 12.07.01.009; 23.03.01.009---
Application site dryness08.02.01.011; 12.07.01.011; 23.03.03.024---
Application site inflammation08.02.01.024; 12.07.01.0240.002283%-
Application site papules08.02.01.025; 12.07.01.025; 23.03.03.022---
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene